Quantification of functional selectivity at the human α(1A)-adrenoceptor

Area of Science:

• Pharmacology
• Molecular Biology
• Biochemistry

Background:

• G protein-coupled receptors (GPCRs) often exhibit promiscuous coupling, activating multiple signaling pathways.
• Agonists can selectively activate pathways by inducing distinct receptor conformational states.

Purpose of the Study:

• To investigate agonist-induced signaling bias at the human alpha(1A)-adrenoceptor.
• To quantify bias in Ca(2+) release, cAMP accumulation, and extracellular acidification rate (ECAR) using an operational model of agonism.

Main Methods:

• Utilized an operational model of agonism to determine signaling bias factors.
• Compared novel agonists (oxymetazoline, phenylephrine, cirazoline, A61603) against the endogenous agonist norepinephrine.
• Measured Ca(2+) release, cAMP accumulation, and ECAR in response to various agonists.

Main Results:

• Oxymetazoline was a full agonist for ECAR and partial for Ca(2+) release, but inactive for cAMP.
• Phenylephrine demonstrated significant bias toward ECAR over Ca(2+) release and cAMP.
• Cirazoline and A61603 showed bias toward cAMP relative to Ca(2+) release.
• Epinephrine did not display bias relative to norepinephrine.

Conclusions:

• Agonist structure dictates signaling bias at the alpha(1A)-adrenoceptor, influencing downstream pathways.
• Subtle structural differences in agonists can lead to distinct receptor conformations and biased effector activation.
• Understanding biased agonism is crucial for developing targeted therapeutics with improved efficacy and reduced side effects.